Program
ravulizumab
Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.
Drug pageRavulizumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 349 open or running | phase 4since Mar 23, 2020 | Nov 2, 2015 | Jun 25, 2027phase 4 · NCT07308574 |
| Regeneron Pharmaceuticalsits history only | 10 open or running | phase 3since Nov 12, 2021 | Nov 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 18 earlier studies, Nov 2, 2015 to Aug 4, 2021.
- Jun 9, 2017Named ravulizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, ALXN1210
- Nov 12, 2021Regeneron Pharmaceuticals’ first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT05131204 · 3 enrolled · United States
- Mar 11, 20224 phase 1 studies in HealthyAstraZeneca · NCT05288829, NCT05288816, NCT05288673 and 1 more
- Apr 20, 2022Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT05346354 · 12 enrolled · United States, Canada, France and more
- May 25, 2022Phase 1 study in HealthyAstraZeneca · NCT05396742 · 49 enrolled · United Kingdom
- Dec 1, 2022Phase 3 study in Myasthenia GravisAstraZeneca · NCT05644561 · 12 enrolled · United States, Italy, Japan and more
- Feb 16, 2023Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT05746559 · 555 enrolled · United States, Argentina, Australia and more
- Feb 26, 2024Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT06291376 · 584 enrolled · United States, Argentina, Australia and more
- Aug 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalAstraZeneca · NCT06578949 · 18 enrolled · China
- Feb 10, 2025Phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798 · 450 planned · United States, Argentina, Australia and more
- Jun 9, 2025Phase 3 study in Glomerulonephritis, IGAAstraZeneca · NCT07024563 · 36 planned · United States, China, Italy and more
- Oct 3, 2025Phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838 · 75 planned · United States, Germany, Italy and more
- Dec 17, 2025Phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574 · 20 planned · Japan
- Apr 23, 2026Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT07557420 · 19 planned · China
- May 13, 2026Phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784 · 20 planned · China
Ahead
- Jun 25, 2027Primary completion: phase 4 study in Atypical Hemolytic Uremic SyndromeAstraZeneca · NCT07308574
- Aug 24, 2027Primary completion: phase 3 study in Myasthenia GravisAstraZeneca · NCT07596784
- Aug 27, 2027Primary completion: phase 4 study in Myasthenia GravisAstraZeneca · NCT07221838
- Nov 30, 2027Primary completion: phase 3 study in Delayed Graft FunctionAstraZeneca · NCT06830798
TargetBeta
“Complement C5 inhibitor”ChEMBL 37, by rule
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
| ABBV-6628 | AbbVie | phase 2 | 1 |
Studies
All 35 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07596784Myasthenia Gravis · China | 3 | Recruiting | AstraZeneca | Aug 24, 2027 | 20 |
| NCT07557420Neuromyelitis Optica · China | 3 | Recruiting | AstraZeneca | Sep 19, 2028 | 19 |
| NCT07308574Atypical Hemolytic Uremic Syndrome · Japan | 4 | Recruiting | AstraZeneca | Jun 25, 2027 | 20 |
| NCT07221838Myasthenia Gravis · United States, Germany, Italy and more | 4 | Recruiting | AstraZeneca | Aug 27, 2027 | 75 |
| NCT07024563Glomerulonephritis, IGA · United States, China, Italy and more | 3 | Recruiting | AstraZeneca | Nov 29, 2028 | 36 |
| NCT06830798Delayed Graft Function · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Nov 30, 2027 | 450 |
| NCT06578949Hemoglobinuria, Paroxysmal · China | 3 | Completed | AstraZeneca | May 15, 2025 | 18 |
| NCT06291376Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Jan 5, 2026 | 584 |
| NCT05746559Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Terminated | AstraZeneca | Oct 7, 2025 | 555 |
| NCT05644561Myasthenia Gravis · United States, Italy, Japan and more | 3 | Active, not recruiting | AstraZeneca | Jul 15, 2026 | 12 |
| NCT05396742Healthy · United Kingdom | 1 | Completed | AstraZeneca | May 21, 2019 | 49 |
| NCT05346354Neuromyelitis Optica · United States, Canada, France and more | 3 | Active, not recruiting | AstraZeneca | Jun 22, 2026 | 12 |
| NCT05288829Healthy · United Kingdom | 1 | Completed | AstraZeneca | Jul 18, 2017 | 42 |
| NCT05288816Healthy · United Kingdom | 1 | Completed | AstraZeneca | Jul 5, 2017 | 16 |
| NCT05288673Healthy · United Kingdom | 1 | Completed | AstraZeneca | Sep 1, 2016 | 16 |
| NCT05288660Healthy · Canada | 1 | Completed | AstraZeneca | Mar 13, 2015 | 14 |
| NCT05131204Hemoglobinuria, Paroxysmal · United States | 3 | Terminated | Regeneron Pharmaceuticals | Jul 12, 2023 | 3 |
| NCT04999020Dermatomyositis · United States, Australia, Brazil and more | 3 | Terminated | AstraZeneca | Oct 26, 2023 | 38 |
| NCT04743804Thrombotic Microangiopathies · United States, Belgium, Brazil and more | 3 | Terminated | AstraZeneca | Dec 22, 2022 | 16 |
| NCT04564339Lupus Nephritis · United States, Australia, Canada and more | 2 | Terminated | AstraZeneca | Mar 26, 2025 | 123 |
| NCT04557735Thrombotic Microangiopathies · United States, Israel, Italy and more | 3 | Completed | AstraZeneca | Nov 26, 2024 | 41 |
| NCT04543591Thrombotic Microangiopathies · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Sep 19, 2025 | 148 |
| NCT04369469Acute Lung Injury · United States, France, Japan and more | 3 | Terminated | AstraZeneca | Feb 8, 2021 | 202 |
| NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom | 4 | Completed | AstraZeneca | Dec 20, 2022 | 18 |
| NCT04248465Amyotrophic Lateral Sclerosis · United States, Australia, Belgium and more | 3 | Terminated | AstraZeneca | Oct 17, 2021 | 382 |
| NCT04201262Neuromyelitis Optica · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Mar 15, 2022 | 58 |
| NCT03920293Myasthenia Gravis · United States, Austria, Canada and more | 3 | Completed | AstraZeneca | May 11, 2021 | 175 |
| NCT03748823Hemoglobinuria, Paroxysmal · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Feb 2, 2021 | 139 |
| NCT03406507Hemoglobinuria, Paroxysmal · United States, France, Netherlands and more | 3 | Completed | AstraZeneca | Mar 25, 2020 | 13 |
| NCT03131219Atypical Hemolytic Uremic Syndrome · United States, Belgium, Germany and more | 3 | Completed | AstraZeneca | Dec 20, 2022 | 34 |
| NCT03056040Hemoglobinuria, Paroxysmal · United States, Australia, Canada and more | 3 | Completed | AstraZeneca | Feb 21, 2022 | 202 |
| NCT02949128Atypical Hemolytic Uremic Syndrome · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | Jan 24, 2023 | 58 |
| NCT02946463Hemoglobinuria, Paroxysmal · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Feb 28, 2023 | 272 |
| NCT02605993Hemoglobinuria, Paroxysmal · Canada, France, Germany and more | 2 | Completed | AstraZeneca | Feb 23, 2017 | 26 |
| NCT02598583Hemoglobinuria, Paroxysmal · Australia, Korea, Republic of | 2 | Completed | AstraZeneca | Jul 14, 2016 | 13 |
How it is read
Names in the registry
- “Ravulizumab”, 30 entries
- “ALXN1210”, 4 entries
- “ALXN1210 SC”, 1 entry
- “ALXN1210 IV”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 9 studies
- Myasthenia Gravis, 4 studies
- Thrombotic Microangiopathies, 3 studies
- Neuromyelitis Optica, 3 studies
- Atypical Hemolytic Uremic Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.